A cross-border acquisition can be commercially attractive and still face a difficult closing. Competition review, investment screening, company-law formalities and sector consents may depend on different facts and follow different timetables. The purchase agreement needs to reflect those dependencies.
Our firm advises Israeli companies and foreign multinationals on the legal structure, transaction agreements and regulatory coordination of cross-border deals. We identify the approvals relevant to the proposed transaction, coordinate local advice and negotiate how the parties will share information, respond to conditions and address delay.
Identify the transaction before planning the approvals
A statutory merger, share acquisition, asset purchase and internal reorganization can have different legal effects. We establish the entities, assets, control rights and jurisdictions involved before advising on a filing route. The target’s place of incorporation is one part of that inquiry; its operations, customers, subsidiaries and regulated activities also matter.
The European Parliament study on cross-border mergers examines the development and practical difficulties of the European merger framework. Our firm uses that history to identify transaction questions, then checks the current corporate-law route and national implementation for the entities involved.
For example, a proposed purchase of a European group with an Israeli technology subsidiary calls for an entity and asset map. We examine the ownership chain, intellectual property, financing, important contracts and required consents, then connect the findings to the proposed signing and closing conditions.
Build one filing map with separate legal tracks
The OECD discussion of cross-border merger review examines differences in jurisdiction, review timing and remedies. Our firm prepares a transaction-specific map that gives each potential filing an owner, legal trigger, information requirement and closing consequence.
Competition review asks questions about the transaction and its effect on markets. Investment screening may focus on ownership, control and sensitive activities. Tax, corporate, employment, securities and sector requirements need their own analysis. We coordinate those questions so that a change to the structure or timetable reaches the advisers responsible for each affected track.
| Workstream | What our firm examines | Effect on the agreement |
|---|---|---|
| Competition | Control, group turnover, activities and market overlap | Filing duties, cooperation and clearance conditions |
| Investment and sector review | Investor ownership, sensitive assets and regulated business | Approval conditions and limits on acceptable restrictions |
| Corporate steps | Entity eligibility, approvals, creditor and shareholder safeguards | Documents and conditions for legal effectiveness |
| Tax and financing | Structure, withholding, financing and any ruling requirements | Payment mechanics and allocation of tax exposure |
| Employees and information | Consultation, transfers, data access and communications | Timing, responsibilities and integration controls |
| Contracts and assets | Change-of-control clauses, assignments, licenses and security | Third-party consents and treatment of continuing obligations |
Separate the EU corporate route from competition clearance
The earlier Directive 2005/56/EC formed part of the development of the EU cross-border merger framework. It was codified in Directive (EU) 2017/1132, which was later amended, including by Directive (EU) 2019/2121 on cross-border conversions, mergers and divisions. Our firm checks the current framework and its national implementation, including company eligibility and safeguards for shareholders, creditors and employees.
The statutory merger process and competition review have different functions. We identify the required corporate documents, approvals and legality checks, and establish when the merger can take legal effect under the applicable national law. Those steps belong alongside the regulatory clearances in the closing plan.
The OECD merger-control material provides background on cross-border competition review. Under the EU Merger Regulation, one jurisdictional test requires combined worldwide turnover exceeding EUR 5 billion and EU-wide turnover exceeding EUR 250 million for each of at least two undertakings concerned, subject to the same-Member-State two-thirds exception. The Regulation also contains an alternative turnover test and referral mechanisms. Our firm checks the full jurisdictional analysis and turnover allocation for the proposed deal.
The EU Foreign Subsidies Regulation creates a separate concentration-notification process where its conditions are met, with a standstill obligation. The Commission’s official guidance identifies the notification regime operating from 12 October 2023. We coordinate the financial-contribution inquiry with competition work and establish the applicable notification and closing restrictions for the particular transaction.
Turn the filing map into a workable timetable
We distinguish signing, announcement, submission of a complete filing, clearance, shareholder approval, legal effectiveness and closing. Each milestone needs an identified basis and supporting documents. Management can then see which work can proceed in parallel and which step depends on another result.
Our firm coordinates the factual account used across jurisdictions: the parties, ownership, activities, customers, financing and proposed structure. We address inconsistencies before submissions and arrange an agreed process for updating the advisers when the transaction changes.
For an Indian element, the discussion of India’s updated cross-border merger approval pathway identifies an approval issue for local review. Our firm coordinates confirmation of the operative corporate and foreign-exchange route, competent authority and required documents before making that route a closing assumption.
| Milestone | Required decision | Our firm’s work |
|---|---|---|
| Before signing | Can the proposed structure obtain the necessary approvals? | Coordinate jurisdictional analysis and identify material risks |
| Transaction agreement | Who bears delay and remedy risk? | Negotiate conditions, cooperation, remedy limits and termination rights |
| Filing preparation | What facts and documents support the submissions? | Coordinate information requests, translations and consistency review |
| Regulatory review | How will the parties answer questions or negotiate conditions? | Manage responses with the relevant advisers and assess proposed remedies |
| Closing | Are the agreed conditions and legal steps satisfied? | Review clearances, consents and completion documents |
| After closing | Which obligations continue? | Track remedy conditions, reporting, governance and contractual commitments |
Allocate regulatory risk in the purchase agreement
Our firm negotiates responsibility for filings, access to information, approval of submissions and contact with authorities. We define cooperation duties and address the position if one party supplies incomplete information or changes the structure during review.
Remedy obligations need commercial limits. A proposed divestiture, governance restriction or access commitment may affect the value of the acquired business. We connect the legal conditions to management’s acceptable outcome, including the assets or activities that the buyer is prepared to give up.
The long-stop date should reflect identified dependencies and the parties’ financing position. We negotiate extensions, termination rights, costs and any agreed financial consequences. Where an approval is delayed, we assess the contract and available options before advising on an extension, revised structure or dispute.
Protect the business while approvals are pending
Our firm reviews interim operating covenants and information-sharing arrangements against the relevant pre-clearance restrictions. We identify who may receive sensitive material, how advisers will use it and what decisions remain with the target before lawful completion.
A clean-team arrangement should support the diligence question that needs answering. We coordinate access restrictions, reporting and escalation with the relevant advisers, while keeping the transaction team informed of findings it can lawfully use.
Public messaging also needs an agreed sequence. We address announcements, shareholder materials, employee communications and responses to a leak with the relevant legal and communications advisers. The transaction agreement should support that process through clear approval and cooperation provisions.
Assess changing guidance and proposed remedies together
The analysis of EU merger control and foreign-subsidy screening discusses the relationship between competition and subsidy screening. The Commission published draft revised Merger Guidelines on 30 April 2026 and closed the consultation on 26 June 2026. Its review page describes a continuing process toward finalization. Our firm distinguishes the draft from the applicable legal framework when assessing a live transaction.
A proposed remedy should be tested across the affected reviews. An asset sale may change the transaction perimeter; a governance restriction may affect control; an access undertaking may require a separate information or licensing arrangement. We coordinate those effects before the parties commit to the proposed solution.
Respond when the timetable or transaction breaks down
A missed filing, disputed condition or unauthorized early integration calls for a prompt assessment of the facts, applicable restrictions and contractual rights. Our firm coordinates preservation of the transaction record, specialist advice and communications, then advises on the response and available commercial options.
Guidance on how to handle a legal crisis can help frame communications planning. We connect that planning to the legal position, including the authority’s requirements, disclosure duties and the parties’ agreement. Where a dispute develops, we prepare correspondence, negotiate a supported solution and represent the client in the appropriate proceedings.
Can signing and closing occur together?
We assess the transaction’s approvals and restrictions before advising on that structure. Where a prior clearance or corporate step is required, we draft the agreement and completion mechanics around it.
What changes if the target has an Israeli subsidiary?
Our firm examines the Israeli business, contracts, assets, intellectual property and any relevant regulatory conditions. We coordinate that review with the foreign transaction so that local obligations are addressed in the agreement and closing plan.
What happens after clearance?
We review the actual decision and any continuing conditions, then assign the required completion and post-closing work. The handover should connect regulatory commitments to the people responsible for governance, reporting, assets and integration.
A cross-border merger lives or dies on regulatory approvals you did not plan for.
Antitrust filings, foreign-investment review and sector approvals run on their own clocks. Missing one in the timeline can kill the deal or the price.
We steer cross-border mergers through Israeli and foreign regulatory review. Reach us on WhatsApp or by email.
RNC Group advises Israeli companies and foreign multinationals on cross-border transaction agreements, regulatory coordination and related disputes. Contact our firm to discuss the proposed structure, approval risks and negotiating position before signing.
This article is for general information only and does not constitute legal advice. Laws and their application depend on the facts and jurisdiction and may change. Although we aim to keep this information accurate and current, we do not guarantee that it is complete or up to date. The article may contain omissions or errors. Reading this article does not create an attorney-client relationship with RNC Group. Before making a decision or taking action, seek advice from a qualified lawyer in the relevant jurisdiction.